用于皮肤给药的阿昔洛韦固体脂质纳米颗粒:制备、表征和体外研究。

Q3 Pharmacology, Toxicology and Pharmaceutics
K. Bhupinder, M. Newton
{"title":"用于皮肤给药的阿昔洛韦固体脂质纳米颗粒:制备、表征和体外研究。","authors":"K. Bhupinder, M. Newton","doi":"10.2174/1872211311666170117123403","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\nThe fractionated coconut oil based Solid Lipid Nanoparticles (SLNs) of Acyclovir (ACV) were fabricated in two batches by using Glyceryl mono stearate (GMS) and Lipoid S75 (Fat free soybean phospholipids with 70% phosphatidylcholine-Lipoid GmbH, Germany). The research was focused on developing ACV-SLN by using high pressure hot-homogenization technique. The ingredients were used in different concentrations and ratios to identify the best formulation design.\n\n\nMETHODS\nThe GMS with Fractionated coconut oil and Lipoid S75 with Fractionated coconut oil were used in various concentrations in formulation design to assess the impact on the fabrication and evaluation of SLNs. The SLNs were subjected to various characterization techniques such as XRD (X-Ray Diffraction), FTIR (Fourier transform infrared study), master sizer analysis and zeta potential. The mean particle size was determined by master sizer and zeta sizer. Transmission Electron Microscopy (TEM) was used as a tool to analyze the morphology and other features. The zeta potential and drug Entrapment Efficiency (EE%) were also determined. The drug release time profile was studied in vitro study with the utilization of dialysis membrane technique as well as by wistar rat skin. The most recent patents related to the current research topic were also discussed.\n\n\nRESULTS\nThe Zeta potential of the best formulation from GMS batch GNE5 was found to be -2.62mV as the preparation was very viscous with low zeta potential. The better results of Lipoid S75 batch LS4 were found to be 23.23mV which was within the recommended range. The formulations prepared with Lipoid S75, LS4 showed narrow distribution size of 53.46nm and the uniformity was found to be 14.1. The formulation LS4 demonstrated the lowest distribution with of 6.8, 14.5, 139.1nm respectively amongst all the formulations.\n\n\nCONCLUSION\nSLN dispersions exhibited the average size in nano range. SLNs with small particle size found to have predetermined encapsulation efficiency and relatively high loading capacity and predetermined in vitro drugrelease profile. The lipoid S and Pluronic F68 nanoparticles are found to be superior to Conventional GMSand tween 80 nanoparticles in terms of particles size, stability and zetapotential.","PeriodicalId":40024,"journal":{"name":"Recent Patents on Drug Delivery and Formulation","volume":"11 2 1","pages":"132-146"},"PeriodicalIF":0.0000,"publicationDate":"2017-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":"{\"title\":\"Acyclovir Solid Lipid Nanoparticles for Skin Drug Delivery: Fabrication, Characterization and In vitro Study.\",\"authors\":\"K. Bhupinder, M. Newton\",\"doi\":\"10.2174/1872211311666170117123403\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBJECTIVE\\nThe fractionated coconut oil based Solid Lipid Nanoparticles (SLNs) of Acyclovir (ACV) were fabricated in two batches by using Glyceryl mono stearate (GMS) and Lipoid S75 (Fat free soybean phospholipids with 70% phosphatidylcholine-Lipoid GmbH, Germany). The research was focused on developing ACV-SLN by using high pressure hot-homogenization technique. The ingredients were used in different concentrations and ratios to identify the best formulation design.\\n\\n\\nMETHODS\\nThe GMS with Fractionated coconut oil and Lipoid S75 with Fractionated coconut oil were used in various concentrations in formulation design to assess the impact on the fabrication and evaluation of SLNs. The SLNs were subjected to various characterization techniques such as XRD (X-Ray Diffraction), FTIR (Fourier transform infrared study), master sizer analysis and zeta potential. The mean particle size was determined by master sizer and zeta sizer. Transmission Electron Microscopy (TEM) was used as a tool to analyze the morphology and other features. The zeta potential and drug Entrapment Efficiency (EE%) were also determined. The drug release time profile was studied in vitro study with the utilization of dialysis membrane technique as well as by wistar rat skin. The most recent patents related to the current research topic were also discussed.\\n\\n\\nRESULTS\\nThe Zeta potential of the best formulation from GMS batch GNE5 was found to be -2.62mV as the preparation was very viscous with low zeta potential. The better results of Lipoid S75 batch LS4 were found to be 23.23mV which was within the recommended range. The formulations prepared with Lipoid S75, LS4 showed narrow distribution size of 53.46nm and the uniformity was found to be 14.1. The formulation LS4 demonstrated the lowest distribution with of 6.8, 14.5, 139.1nm respectively amongst all the formulations.\\n\\n\\nCONCLUSION\\nSLN dispersions exhibited the average size in nano range. SLNs with small particle size found to have predetermined encapsulation efficiency and relatively high loading capacity and predetermined in vitro drugrelease profile. The lipoid S and Pluronic F68 nanoparticles are found to be superior to Conventional GMSand tween 80 nanoparticles in terms of particles size, stability and zetapotential.\",\"PeriodicalId\":40024,\"journal\":{\"name\":\"Recent Patents on Drug Delivery and Formulation\",\"volume\":\"11 2 1\",\"pages\":\"132-146\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent Patents on Drug Delivery and Formulation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1872211311666170117123403\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Patents on Drug Delivery and Formulation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872211311666170117123403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 7

摘要

目的采用单硬脂酸甘油酯(GMS)和脂质S75(含70%磷脂酰胆碱-脂质GmbH,德国)分两批制备无环鸟苷(ACV)固体脂质纳米颗粒(SLNs)。重点研究了采用高压热均质技术制备ACV-SLN。分别以不同的浓度和配比进行试验,确定最佳的配方设计。方法采用不同浓度的椰子油GMS和脂质S75进行配方设计,考察其对sln制备和评价的影响。采用XRD (x射线衍射)、FTIR(傅里叶变换红外研究)、主粒度分析和zeta电位等多种表征技术对sln进行了表征。平均粒径由主浆纱机和zeta浆纱机确定。透射电子显微镜(TEM)作为分析形貌和其他特征的工具。测定了zeta电位和药物包封效率(EE%)。利用透析膜技术和wistar大鼠皮肤对其体外释放时间进行了研究。讨论了与当前研究课题相关的最新专利。结果GMS批号GNE5的最佳配方的Zeta电位为-2.62mV,因为该制剂黏性强,Zeta电位低。脂质S75批次LS4的效果较好,为23.23mV,在推荐范围内。用脂质S75、LS4制备的配方分布尺寸较窄,为53.46nm,均匀度为14.1。配方LS4分布最小,分别为6.8、14.5、139.1nm。结论sln分散体在纳米范围内具有平均尺寸。小粒径的sln具有预定的包封效率、较高的载药量和预定的体外释药特性。脂质S和Pluronic F68纳米颗粒在颗粒大小、稳定性和zetpotential方面优于传统的gms和tween 80纳米颗粒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Acyclovir Solid Lipid Nanoparticles for Skin Drug Delivery: Fabrication, Characterization and In vitro Study.
OBJECTIVE The fractionated coconut oil based Solid Lipid Nanoparticles (SLNs) of Acyclovir (ACV) were fabricated in two batches by using Glyceryl mono stearate (GMS) and Lipoid S75 (Fat free soybean phospholipids with 70% phosphatidylcholine-Lipoid GmbH, Germany). The research was focused on developing ACV-SLN by using high pressure hot-homogenization technique. The ingredients were used in different concentrations and ratios to identify the best formulation design. METHODS The GMS with Fractionated coconut oil and Lipoid S75 with Fractionated coconut oil were used in various concentrations in formulation design to assess the impact on the fabrication and evaluation of SLNs. The SLNs were subjected to various characterization techniques such as XRD (X-Ray Diffraction), FTIR (Fourier transform infrared study), master sizer analysis and zeta potential. The mean particle size was determined by master sizer and zeta sizer. Transmission Electron Microscopy (TEM) was used as a tool to analyze the morphology and other features. The zeta potential and drug Entrapment Efficiency (EE%) were also determined. The drug release time profile was studied in vitro study with the utilization of dialysis membrane technique as well as by wistar rat skin. The most recent patents related to the current research topic were also discussed. RESULTS The Zeta potential of the best formulation from GMS batch GNE5 was found to be -2.62mV as the preparation was very viscous with low zeta potential. The better results of Lipoid S75 batch LS4 were found to be 23.23mV which was within the recommended range. The formulations prepared with Lipoid S75, LS4 showed narrow distribution size of 53.46nm and the uniformity was found to be 14.1. The formulation LS4 demonstrated the lowest distribution with of 6.8, 14.5, 139.1nm respectively amongst all the formulations. CONCLUSION SLN dispersions exhibited the average size in nano range. SLNs with small particle size found to have predetermined encapsulation efficiency and relatively high loading capacity and predetermined in vitro drugrelease profile. The lipoid S and Pluronic F68 nanoparticles are found to be superior to Conventional GMSand tween 80 nanoparticles in terms of particles size, stability and zetapotential.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Recent Patents on Drug Delivery and Formulation
Recent Patents on Drug Delivery and Formulation Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
2.30
自引率
0.00%
发文量
0
期刊介绍: Recent Patents on Drug Delivery & Formulation publishes review and research articles, drug clinical trial studies and guest edited thematic issues on recent patents on drug delivery and formulation. A selection of important and recent patents on drug delivery and formulation is also included in the journal. The journal is essential reading for all researchers involved in the fields of drug delivery and formulation. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to drug delivery and formulations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信